INTRODUCTION
The emergence of Gram-negative multi-drug resistance is an ongoing threat. Pediatric patients are not spared from these resistant organisms. Of particular concern is emerging Gram-negative resistance among pediatric patients with cystic fibrosis (CF), who are frequently exposed to broad-spectrum antibiotic therapy for the treatment of acute pulmonary exacerbations. Multi-drug-resistant Pseudomonas aeruginosa often leaves CF patients with few remaining treatment options and has a significant detrimental impact on patient care, including increased mortality [1] . New antimicrobial agents have been developed for the treatment of multi-drug-resistant organisms (MDRO), but data in pediatric patients are extremely limited.
Ceftolozane/tazobactam (Zerbaxa TM ) was approved by the FDA in December 2014 for the treatment of complicated intra-abdominal and urinary tract infections in adults [2] . Ceftolozane/tazobactam is an extended-spectrum cephalosporin/beta-lactamase inhibitor combination that has been shown to maintain activity against MDR P. aeruginosa strains, including respiratory strains from CF patients [3] [4] [5] [6] . 
Time-Kill Analyses
Time-kill analyses were performed on each of the 5 P. aeruginosa isolates. Each isolate was subcultured twice on Trypticase Soy Agar with Aminoglycoside concentrations were determined to mimic peak concentrations achieved with once-daily dosing in children. [9] Control experiments without active compound were conducted simultaneously with the time-kill studies. Final volumes for each bacterium-drug concentration were 10 mL and incubated at 37°C. Samples were taken from each sample at 0, 3, 6, and 24 h from the time of adding the drug. Multiple 1:10 dilutions were made in saline and sub-cultured onto blood agar plates and incubated for 18-24 h, and mean bacterial densities were determined for each isolate. The minimal, accurately countable number of CFU/mL was determined to be 5 9 10 -1 CFU/mL.
[10] All studies were conducted in duplicate on different days, and the combined data are presented as mean bacterial density (CFU/mL) for all isolates. Bactericidal activity was defined as a decrease of C3-log 10 from baseline bacterial density. Synergy was defined as a C2-log 10 decrease in CFU/mL between the antibiotic combination and its most active constituent after 24 h when the number of surviving organisms in the presence of the combination was C2-log 10 CFU/mL below the starting inoculum [10]. 
DISCUSSION
To the best of our knowledge, this is the first study to perform time-kill analyses of ceftolozane/tazobactam alone and in combination with other agents against P. aeruginosa isolates from pediatric CF patients.
These data suggest that killing of P. aeruginosa isolates appears to require concentrations of at Table 1 the concentration/MIC ratio of 6.6 suggested to optimize the in vivo antibiotic effect of ceftazidime against P. aeruginosa isolates from CF patients [11] . Further, the retained activity of ceftolozane/tazobactam against the tested mucoid P. aeruginosa strain supports previously published data, and suggests a potential role of this antimicrobial against mucoid strains from The size of this study is a limitation, as only a small number of isolates (n = 5) from a small number of patients (n = 4) were evaluated.
CONCLUSION
Ceftolozane/tazobactam appears to be a promising treatment option for treatment of MDR P. aeruginosa in pediatric CF patients. Interestingly, the benefit of ceftolozane/tazobactam combination therapy with amikacin may be more pronounced than with the addition of tobramycin. Further evaluation of such combination regimens is warranted in pediatric CF patients, specifically when a better understanding of ceftolozane/tazobactam pharmacokinetics in 
